Lexeo Therapeutics is a company developing gene therapy for people with FA cardiomyopathy. They recently announced the completion of the first cohort in their Phase I/II trial, testing their gene therapy called LX2006.
In the first cohort, LX2006 was well tolerated with no unexpected events observed. Based on this, they have begun dosing the second cohort of participants. This is a 52-week trial taking place in America. They expect results from this trial in the first half of 2024.
Read more in the Lexeo Therapeutics press release.
